Can Less Be More Bladder Cancer Surveillance The Future Fewer Cystoscopies Vs Urine Biomarkers

Inching Towards A World With Fewer Cystoscopies Bladdercancer Net Bladder cancer surveillance & the future: fewer cystoscopies vs urine biomarkers. the johns hopkins greenberg bladder cancer institute grand rounds 2025 continues with dr zhuo. Urologist dr. max kates, md, director of the brady urological institute's bladder cancer program, leads a conversation with a patient focused around what bladder cancer patients can expect after treatments stop, including scans and surveillance how often and why.

Bladder Cancer Biomarkers Surveillance Specifically, we need evidence that programmatic surveillance with urine markers decreases the burden of surveillance significantly for patients and has acceptable oncological outcomes in diverse populations of bladder cancer survivors. Reducing follow up procedures such as cystoscopies and turbt in low grade risk non muscle invasive bladder cancer (nmibc) patients is imperative to reduce the burden for patients, increase compliance, and reduce procedure complications. Ideally, we would have non invasive urine based tests available to identify patients who could safely defer surveillance cystoscopy. however, it appears that the patient required benchmarks for these tests to replace cystoscopy are high. The future of active surveillance in bladder cancer should involve better patient selection that relies on risk factors, enhanced modalities through imaging and biomarkers, and the advent.

Pdf Biomarkers In Bladder Cancer Surveillance Ideally, we would have non invasive urine based tests available to identify patients who could safely defer surveillance cystoscopy. however, it appears that the patient required benchmarks for these tests to replace cystoscopy are high. The future of active surveillance in bladder cancer should involve better patient selection that relies on risk factors, enhanced modalities through imaging and biomarkers, and the advent. In this review, we provide a comprehensive overview of currently available and recently reported promising urinary markers for the diagnosis and follow up of bca. additionally, we discussed the challenges and prospects of these urinary markers for clinical implementation. Urine is directly exposed to bladder tumours and, therefore, is an ideal source for biomarker discovery in bladder cancer. numerous urine based assays have been developed for diagnostic. For these reasons, new biomarkers for a less invasive, more sensitive, and more cost effective diagnosis of bc are urgently needed in order to replace the low sensitivity of urinary cytology (uc) and the invasiveness of cystoscopy (10). Future research should compare the performance of uroseek with known urine biomarkers, assess its cost effectiveness, and establish whether it can minimize the need for invasive cystoscopy in bladder cancer surveillance.